Skip to main content

Advertisement

Table 2 Cox regression analyses for progression-free survival and overall survival in all patients

From: Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study

   Univariate Multivariate
   Hazard ratio (95 % CI) P-value Hazard ratio (95 % CI) P-value
Progression-free survival
EILD Yes 1.80   0.013 1.44   0.16
  No   1.11–2.88    0.86–2.41  
Age 5656 0.76   0.14 0.76   0.19
  >56   0.52–1.10    0.51–1.15  
PS 0 1.41   0.089 1.49   0.073
  1,2   0.95–2.10    0.96–2.31  
Comorbid disease Yes 1.44   0.12 1.51   0.13
  No   0.91–2.28    0.88–2.58  
DFI 2.82.8 1.41   0.069 1.27   0.27
  >2.8   0.97–2.06    0.83–1.95  
BMI >25 1.64   0.036 1.22   0.47
  2525   1.03–2.59    0.71–2.07  
HR (ER/PgR) status Positive 1.49   0.062 1.25   0.37
  Negative   0.98–2.28    0.77–2.03  
HER2 status Negative 1.60   0.067 1.32   0.30
  Positive   0.97–2.65    0.77–2.26  
Liver metastasis No 0.95   0.067 0.93   0.72
  Yes   0.65–1.38    0.63–1.38  
Overall survival
EILD Yes 2.22   0.038 1.75   0.17
  No   1.05–4.71    0.78–3.91  
Age 5656 0.81   0.45 0.77   0.37
  >56   0.47–1.39    0.43–1.36  
PS 0 2.34   0.0021 2.37   0.0039
  1,2   1.36–4.03    1.32–4.26  
Comorbid disease Yes 0.91   0.77 1.04   0.91
  No   0.49–1.70    0.51–2.13  
DFI 2.82.8 1.78   0.038 1.53   0.18
  >2.8   1.03–3.07    0.83–2.85  
BMI >25 1.33   0.39 1.13   0.75
  2525   0.69–2.52    0.55–2.31  
HR (ER/PgR) status Positive 1.67   0.089 1.15   0.70
  Negative   0.93–3.01    0.57–2.29  
HER2 status Negative 1.87   0.093 1.42   0.39
  Positive   0.90–3.88    0.64–3.16  
Liver metastasis No 0.96   0.89 1.00   0.99
  Yes   0.56–1.64    0.56–1.79  
  1. Abbreviation: 95 % CI 95 % confidence interval, EILD eribulin-induced liver dysfunction, PS performance status, DFI disease free interval, BMI body mass index, HR hormone receptor, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2